iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

iTeos Therapeutics, Inc. (NASDAQ ... The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b ...

This page features the latest news about the Iteos stock. Iteos Therapeutics stock hits 52-week low at $8.49 Iteos Therapeutics Inc. (NASDAQ: ITOS) stock has reached a 52-week low, touching down ...

Arcus Biosciences has a promising pipeline with five Phase 3 trials focused on GI and NSCLC cancers. Learn why RCUS stock ...

This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus ...

This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus zimberelimab ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

‘A TOADY’: Lau, a Chinese political advisory body member, sparked controversy with his song “Chinese People” and the concert was said to be part of China’s “united front” tactics Employment ...